What is Wedbush’s Forecast for WVE FY2028 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Investment analysts at Wedbush issued their FY2028 earnings estimates for shares of Wave Life Sciences in a report released on Thursday, May 8th. Wedbush analyst Y. Zhong anticipates that the company will earn ($0.88) per share for the year. Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Wave Life Sciences’ FY2029 earnings at ($0.64) EPS.

A number of other equities research analysts have also commented on WVE. Cantor Fitzgerald assumed coverage on shares of Wave Life Sciences in a report on Tuesday, April 29th. They set an “overweight” rating and a $10.00 price target for the company. StockNews.com lowered shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, May 9th. Jefferies Financial Group began coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.17.

Wave Life Sciences Stock Down 3.2%

NASDAQ:WVE opened at $6.39 on Monday. The company has a fifty day moving average of $7.70 and a 200 day moving average of $11.08. Wave Life Sciences has a 52 week low of $4.25 and a 52 week high of $16.74. The firm has a market capitalization of $984.64 million, a P/E ratio of -5.76 and a beta of -0.92.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The firm had revenue of $9.18 million for the quarter, compared to the consensus estimate of $11.65 million. During the same quarter in the prior year, the company earned ($0.24) earnings per share.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. This trade represents a 33.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christian O. Henry sold 10,500 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the sale, the director now directly owns 16,115 shares in the company, valued at $157,443.55. This trade represents a 39.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 29.10% of the company’s stock.

Institutional Trading of Wave Life Sciences

Several institutional investors have recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Wave Life Sciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 18,673 shares of the company’s stock valued at $151,000 after purchasing an additional 1,564 shares during the last quarter. Victory Capital Management Inc. grew its position in Wave Life Sciences by 16.6% during the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company’s stock valued at $180,000 after purchasing an additional 2,073 shares during the last quarter. Bank of New York Mellon Corp grew its position in Wave Life Sciences by 0.9% during the 1st quarter. Bank of New York Mellon Corp now owns 247,251 shares of the company’s stock valued at $1,998,000 after purchasing an additional 2,278 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after acquiring an additional 2,308 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in Wave Life Sciences during the 4th quarter valued at about $40,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.